CAS No.: 864070-44-0
恩格列净 Catalog No. CSN13801
Synonyms: BI 10773;CE0108;CS0940
Empagliflozin is a selective inhibitor of SGLT-2 with IC50 of 3.1 nM.
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
靶点 SGLT2
IC50:3.1nM- 描述
- 作用机制
动物研究 剂量 Rat: 3 mg/kg, 10 mg/kg[3] (p.o.), 10 mg/kg - 30 mg/kg[4] (i.g.) Mice: 3 mg/kg, 10 mg/kg[5] (p.o.), 35 mg/kg[6] (p.o.)
给药途径 p.o., i.g.
动物药代数据 Animal Mice[7] Dose 5 mg/kg (i.v., male)
250 mg/kg (p.o., male)Administration i.v.
p.o.MRT 0.488 h (i.v.)
2.52 h (p.o.)F 89.8% (p.o.) T1/2 1.26 h (i.v.)
5.59 h (p.o.)Tmax 0.67 h (p.o.) CL 40.1 ml/min/kg (i.v.)
44.6 ml/min/kg (p.o.)Cmax 97700 nM (p.o.) Vss 1.17 L/kg (i.v.) AUC 4610 μM·h (i.v.)
207000 μM·h (p.o.)- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT02729766 Inappropriate ADH Syndrome Phase 2 Phase 3 Completed - Switzerland ... more >> Department Endocrinology University Hospital Basel Basel, Switzerland, 4031 Collapse << NCT01301742 Healthy Phase 1 Completed - Germany ... more >> 1245.58.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << NCT01301742 - - Completed - - - 更多
- 参考文献
- [1] Panchapakesan U, Pegg K, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442.
- [2] Thomas L, Grempler R, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012 Jan;14(1):94-6.
- [3] Lee KA, Jin HY, et al. Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats. Diabetes Metab J. 2018 Aug;42(4):338-342.
- [4] Shao Q, Meng L, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019 Nov 28;18(1):165.
- [5] Cheng ST, Chen L, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11(1):e0147391.
- [6] Pennig J, Scherrer P, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep. 2019 Nov 29;9(1):17937.
- [7] Empagliflozin
- [8] Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90.
- [9] Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD. Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. JACC Basic Transl Sci. 2018 Aug 26;3(5):575-587.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 864070-44-0 | 储存条件 |
|
|||||||||||
| 分子式 | C23H27ClO7 | 运输 | 蓝冰 | |||||||||||
| 分子量 | 450.91 | 别名 | BI 10773;CE0108;CS0940;PB23119;VA10802;AJ93046;trade name Jardiance;恩格列净;依帕列净 | |||||||||||
| 溶解度 |
|
动物实验配方 |
|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
|---|
| NCT02729766 | Inappropriate ADH Syndrome | Phase 2 Phase 3 | Completed | - | Switzerland ... more >> Department Endocrinology University Hospital Basel Basel, Switzerland, 4031 Collapse << |
| NCT01301742 | Healthy | Phase 1 | Completed | - | Germany ... more >> 1245.58.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << |
| NCT01301742 | - | - | Completed | - | - |
| NCT02182830 | Diabetes Mellitus, Type 2 ... more >> Hypertension Collapse << | Phase 3 | Completed | - | - |
| NCT01242176 | Healthy | Phase 1 | Completed | - | Germany ... more >> 1245.51.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << |
| NCT01242176 | - | - | Completed | - | - |
| NCT02182830 | - | - | Completed | - | - |
| NCT02489968 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
| NCT02489968 | - | - | Completed | - | - |
| NCT03259490 | Healthy | Phase 1 | Completed | - | Germany ... more >> Humanpharmakologisches Zentrum Biberach Biberach, Germany, 88397 Collapse << |
| NCT02453555 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | Japan ... more >> 1275.19.81519 Boehringer Ingelheim Investigational Site Aichi, Nagoya, Japan 1275.19.81536 Boehringer Ingelheim Investigational Site Chiba, Kashiwa, Japan 1275.19.81530 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 1275.19.81529 Boehringer Ingelheim Investigational Site Fukuoka, Itoshima, Japan 1275.19.81531 Boehringer Ingelheim Investigational Site Fukuoka, Kurume, Japan 1275.19.81504 Boehringer Ingelheim Investigational Site Fukushima, Koriyama, Japan 1275.19.81528 Boehringer Ingelheim Investigational Site Hiroshima, Hiroshima, Japan 1275.19.81501 Boehringer Ingelheim Investigational Site Hokkaido, Sapporo, Japan 1275.19.81502 Boehringer Ingelheim Investigational Site Hokkaido, Sapporo, Japan 1275.19.81503 Boehringer Ingelheim Investigational Site Hokkaido, Sapporo, Japan 1275.19.81532 Boehringer Ingelheim Investigational Site Hokkaido, Sapporo, Japan 1275.19.81505 Boehringer Ingelheim Investigational Site Ibaraki, Koga, Japan 1275.19.81533 Boehringer Ingelheim Investigational Site Ibaraki, Naka, Japan 1275.19.81516 Boehringer Ingelheim Investigational Site Kanagawa, Kawasaki, Japan 1275.19.81537 Boehringer Ingelheim Investigational Site Kanagawa, Sagamihara, Japan 1275.19.81538 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama, Japan 1275.19.81520 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 1275.19.81521 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 1275.19.81539 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 1275.19.81517 Boehringer Ingelheim Investigational Site Nagano, Matsumoto, Japan 1275.19.81518 Boehringer Ingelheim Investigational Site Nagano, Matsumoto, Japan 1275.19.81525 Boehringer Ingelheim Investigational Site Osaka, Higashi-Osaka, Japan 1275.19.81523 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1275.19.81526 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1275.19.81527 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1275.19.81540 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1275.19.81522 Boehringer Ingelheim Investigational Site Osaka, Suita, Japan 1275.19.81524 Boehringer Ingelheim Investigational Site Osaka, Takatsuki, Japan 1275.19.81535 Boehringer Ingelheim Investigational Site Saitama, Hanno, Japan 1275.19.81506 Boehringer Ingelheim Investigational Site Saitama, Kawagoe, Japan 1275.19.81507 Boehringer Ingelheim Investigational Site Saitama, Saitama, Japan 1275.19.81534 Boehringer Ingelheim Investigational Site Saitama, Tokorozawa, Japan 1275.19.81509 Boehringer Ingelheim Investigational Site Tokyo, Chiyoda-ku, Japan 1275.19.81508 Boehringer Ingelheim Investigational Site Tokyo, Chuo-ku, Japan 1275.19.81512 Boehringer Ingelheim Investigational Site Tokyo, Chuo-ku, Japan 1275.19.81515 Boehringer Ingelheim Investigational Site Tokyo, Hachioji, Japan 1275.19.81511 Boehringer Ingelheim Investigational Site Tokyo, Koto-ku, Japan 1275.19.81513 Boehringer Ingelheim Investigational Site Tokyo, Meguro-ku, Japan 1275.19.81514 Boehringer Ingelheim Investigational Site Tokyo, Shinagawa-ku, Japan 1275.19.81510 Boehringer Ingelheim Investigational Site Tokyo, Shinjuku-ku, Japan Collapse << |
| NCT02580591 | - | - | Completed | - | - |
| NCT03560375 | Diabetes Mellitus, Type 2 ... more >> Sarcopenia Weight Loss Frailty Collapse << | Phase 4 | Recruiting | November 2020 | Israel ... more >> The Institute of Endocrinology Metabolism and Hypertension Recruiting Tel Aviv, Israel, 64239 Contact: Naftali Stern, Professor +972-3-6973732 naftalis@tlvmc.gov.il Principal Investigator: Naftali Stern, Professor Sub-Investigator: Roy Eldor, PhD Collapse << |
| NCT03629054 | Healthy | Phase 1 | Completed | - | Germany ... more >> Humanpharmakologisches Zentrum Biberach Biberach, Germany, 88397 Collapse << |
| NCT02863328 | Diabetes Diab... more >>etes Mellitus, Type 2 Collapse << | Phase 3 | Completed | - | - |
| NCT02489942 | - | - | Active, not recruiting | May 31, 2020 | Japan ... more >> Multiple Locations, Japan Collapse << |
| NCT02964572 | Type2 Diabetes Mellitus | Not Applicable | Recruiting | October 2018 | Korea, Republic of ... more >> Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center Recruiting Seoul, Korea, Republic of, 03722 Contact: Yong-ho Lee, M.D., Ph.D. 82-2-2228-1943 yholee@yuhs.ac Collapse << |
| NCT01111318 | Hepatic Insufficiency ... more >> Healthy Collapse << | Phase 1 | Completed | - | Romania ... more >> 1245.13.40001 Boehringer Ingelheim Investigational Site Timisoara, Romania Collapse << |
| NCT03485222 | Cardiovascular Diseases | Phase 4 | Recruiting | December 2020 | United States, New York ... more >> Mount Sinai Heart - Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Principal Investigator: Juan J Badimon, PhD Collapse << |
| NCT02580591 | Diabetes Mellitus, Type 1 | Phase 3 | Completed | - | - |
| NCT01111318 | - | - | Completed | - | - |
| NCT03510000 | Type1diabetes | Not Applicable | Recruiting | August 31, 2019 | Canada, Ontario ... more >> Sinai Health System Recruiting Toronto, Ontario, Canada, M5T 3L9 Contact: Andrej Orszag 416-586-4800 class15@lunenfeld.ca Principal Investigator: Bruce A. Perkins, MD Canada, Quebec Institut de recherches cliniques de Montréal Recruiting Montréal, Quebec, Canada, H2W 1R7 Contact: Virginie Messier, B.Sc. 514 987-5500 promd@ircm.qc.ca Principal Investigator: Rémi Rabasa-Lhoret, MD, PhD McGill University Health Center Recruiting Montréal, Quebec, Canada, H3A 2B4 Contact 514-398-4491 haidarlab.dmc@mcgill.ca Principal Investigator: Ahmad Haidar Collapse << |
| NCT01984606 | Diabetes Mellitus, Type 2 | Phase 3 | Withdrawn | February 2017 | - |
| NCT01248364 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | Austria ... more >> 1245.39.43001 Boehringer Ingelheim Investigational Site Graz, Austria Germany 1245.39.49002 Boehringer Ingelheim Investigational Site Neuss, Germany Italy 1245.39.39001 Boehringer Ingelheim Investigational Site Pisa, Italy Collapse << |
| NCT03050619 | - | - | Completed | - | Germany ... more >> Boehringer Ingelheim Investigational Site Ingelheim, Germany Collapse << |
| NCT03766724 | Type2 Diabetes | Phase 1 | Active, not recruiting | January 2019 | Korea, Republic of ... more >> Clinical Trials Center, Severance Hospital Seoul, Korea, Republic of, 03722 Collapse << |
| NCT03594110 | Chronic Kidney Disease | Phase 3 | Not yet recruiting | June 30, 2022 | - |
| NCT02121483 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | United States, Connecticut ... more >> 1245.87.01013 Boehringer Ingelheim Investigational Site New Haven, Connecticut, United States United States, Massachusetts 1245.87.01004 Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States United States, Ohio 1245.87.01002 Boehringer Ingelheim Investigational Site Toledo, Ohio, United States United States, Pennsylvania 1245.87.01012 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States 1245.87.01001 Boehringer Ingelheim Investigational Site Pittsburgh, Pennsylvania, United States France 1245.87.33001 Boehringer Ingelheim Investigational Site Lyon, France Israel 1245.87.97202 Boehringer Ingelheim Investigational Site Beer Sheva, Israel 1245.87.97203 Boehringer Ingelheim Investigational Site Tel Hashomer, Israel Mexico 1245.87.52001 Boehringer Ingelheim Investigational Site Chihuahua, Mexico South Africa 1245.87.27003 Boehringer Ingelheim Investigational Site Bellville, South Africa 1245.87.27002 Boehringer Ingelheim Investigational Site Pretoria, South Africa Collapse << |
| NCT01975220 | Healthy | Phase 1 | Completed | - | United States, Texas ... more >> 1276.13.1 Boehringer Ingelheim Investigational Site Austin, Texas, United States Collapse << |
| NCT01248364 | - | - | Completed | - | - |
| NCT02106923 | Healthy | Phase 1 | Completed | - | United States, Texas ... more >> Boehringer Ingelheim Investigational Site Austin, Texas, United States Collapse << |
| NCT03713190 | End Stage Renal Disease | Phase 2 | Recruiting | December 2020 | Italy ... more >> Department of Endocrinology and Metabolism, University of Pisa Recruiting Pisa, Italy, 56124 Contact: Stefano Del Prato, MD +39 050 995103 stefano.delprato@med.unipi.it Sub-Investigator: Giuseppe Daniele, MD Collapse << |
| NCT02414958 | - | - | Completed | - | - |
| NCT02106923 | - | - | Completed | - | - |
| NCT03226457 | Heart Failure ... more >> Type 2 Diabetes Mellitus Collapse << | Phase 4 | Active, not recruiting | February 2019 | United Kingdom ... more >> University of Dundee, Ninewells Hospital and Medical School Dundee, Angus, United Kingdom, DD1 9SY Collapse << |
| NCT01975220 | - | - | Completed | - | - |
| NCT02414958 | Diabetes Mellitus, Type 1 | Phase 3 | Completed | - | - |
| NCT01451775 | Healthy | Phase 1 | Completed | - | Germany ... more >> 1245.79.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << |
| NCT01451775 | - | - | Completed | - | - |
| NCT02121483 | - | - | Completed | - | - |
| NCT02589626 | Diabetes Mellitus, Type 2 | Phase 4 | Completed | - | Japan ... more >> 1245.106.81011 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 1245.106.81001 Boehringer Ingelheim Investigational Site Fukushima, Koriyama, Japan 1245.106.81010 Boehringer Ingelheim Investigational Site Hiroshima, Fukuyama-shi, Japan 1245.106.81005 Boehringer Ingelheim Investigational Site Ibaraki, Naka, Japan 1245.106.81007 Boehringer Ingelheim Investigational Site Kanagawa, Kawasaki, Japan 1245.106.81016 Boehringer Ingelheim Investigational Site Kanagawa, Yamato-shi, Japan 1245.106.81015 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama-shi, Japan 1245.106.81008 Boehringer Ingelheim Investigational Site Mie, Yokkaichi, Japan 1245.106.81012 Boehringer Ingelheim Investigational Site Osaka, Kashiwara-shi, Japan 1245.106.81013 Boehringer Ingelheim Investigational Site Osaka, Osaka-shi, Japan 1245.106.81009 Boehringer Ingelheim Investigational Site Osaka, Suita, Japan 1245.106.81003 Boehringer Ingelheim Investigational Site Tokyo, Chuo-ku, Japan 1245.106.81006 Boehringer Ingelheim Investigational Site Tokyo, Chuo-ku, Japan 1245.106.81014 Boehringer Ingelheim Investigational Site Tokyo, Hachioji-shi, Japan 1245.106.81002 Boehringer Ingelheim Investigational Site Tokyo, Shinjuku-ku, Japan 1245.106.81004 Boehringer Ingelheim Investigational Site Tokyo, Shinjuku-ku, Japan Collapse << |
| NCT03198585 | Heart Failure With Reduced Eje... more >>ction Fraction Collapse << | Phase 2 | Recruiting | October 2019 | Denmark ... more >> Herlev and Gentofte University Hospital Recruiting Copenhagen, Denmark, 2730 Contact: Jesper Jensen, MD +45 38686258 jesper.jensen.06@regionh.dk Principal Investigator: Morten Schou, MD Sub-Investigator: Jesper Jensen, MD Odense University Hospital Recruiting Odense, Denmark, 5000 Contact: Massar Omar, MD +45 608400609 massar.omar@rsyd.dk Principal Investigator: Jacob E Moller, MD Sub-Investigator: Massar Omar, MD Collapse << |
| NCT02782624 | Healthy | Phase 1 | Completed | - | Germany ... more >> 1276.9.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << |
| NCT01811953 | Healthy | Phase 1 | Completed | - | Germany ... more >> 1276.8.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << |
| NCT03173963 | Diabetic Kidney Disease ... more >> Diabetes Mellitus Type 2 Collapse << | Phase 3 | Recruiting | June 30, 2023 | United States, Arizona ... more >> NIDDK, Phoenix Recruiting Phoenix, Arizona, United States, 85014 Contact: Helen Looker 602-200-5215 helen.looker@nih.gov Collapse << |
| NCT01811953 | - | - | Completed | - | - |
| NCT02864914 | - | - | Active, not recruiting | January 1, 2020 | United Kingdom ... more >> RTI health solutions One Or Multiple Sites, United Kingdom Collapse << |
| NCT01392560 | - | - | Completed | - | - |
| NCT03152552 | Diabetes Type 2 With Heart Fai... more >>lure Collapse << | Phase 2 | Completed | - | - |
| NCT02728453 | Diabetes Mellitus Type 2 | Phase 4 | Active, not recruiting | April 2019 | Germany ... more >> Hannover Medical School Hannover, Germany, 30625 Collapse << |
| NCT03462069 | Diabetes Mellitus | Phase 2 | Recruiting | August 7, 2019 | Germany ... more >> Investigational Site Number 2760001 Recruiting Berlin, Germany, 13353 Collapse << |
| NCT01392560 | Diabetes Mellitus, Type 1 | Phase 2 | Completed | - | Canada, Ontario ... more >> 1245.46.10001 Boehringer Ingelheim Investigational Site Toronto, Ontario, Canada Collapse << |
| NCT03128528 | Chronic Heart Failure | Phase 2 | Recruiting | December 31, 2019 | Germany ... more >> Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg Recruiting Erlangen, Germany, 91054 Contact: Roland E Schmieder, MD +49-9131-85 ext 36245 roland.schmieder@uk-erlangen.de Contact: , MD Principal Investigator: Roland E Schmieder, MD Collapse << |
| NCT03429543 | Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | January 31, 2022 | - |
| NCT01001962 | Hypertension ... more >>Type II Diabetes Collapse << | Phase 4 | Not yet recruiting | January 2020 | Greece ... more >> Hypertension 24h ABPM center Papageorgiou Hospital Not yet recruiting Thessaloniki, Greece Contact: VASILEIOS KOTSIS, PROF Principal Investigator: VASILEIOS KOTSIS, PROF Collapse << |
| NCT01844531 | Healthy | Phase 1 | Completed | - | Germany ... more >> 1276.6.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << |
| NCT03200782 | Postprandial Hypoglycemia ... more >> Bariatric Surgery Late Dumping Syndrome Collapse << | Not Applicable | Completed | - | Switzerland ... more >> University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism Basel, Switzerland, 4056 Basel Collapse << |
| NCT01844531 | - | - | Completed | - | - |
| NCT03748810 | - | - | Recruiting | December 31, 2018 | Korea, Republic of ... more >> Chungbuk National University Hospital Recruiting Cheonju, Chungcheongbuk-do, Korea, Republic of, 28644 Contact: Eu Jeong Ku, MD 82-10-3462-8863 eujeong.ku@gmail.com Collapse << |
| NCT02890745 | Diabetes Mellitus, Type 2 | Phase 2 | Unknown | - | Denmark ... more >> Center for Diabetes Research, Gentofte Hospital Recruiting Hellerup, Denmark, 2900 Contact: Jørgen Rungby, DMSc +45 3977 7539 jr@biomed.au.dk Principal Investigator: Jørgen Rungby, Professor, DMSc Collapse << |
| NCT02985242 | Diabetes Mellitus, Type II | Phase 4 | Terminated(difficulties to rec... more >>ruit planned numbers of patients within reasonable time frame) Collapse << | - | Germany ... more >> Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover Hanover, Lower Saxony, Germany, 30625 Collapse << |
| NCT03591991 | Reperfusion Injury, Myocardial | Not Applicable | Not yet recruiting | September 1, 2019 | - |
| NCT01867307 | - | - | Completed | - | - |
| NCT02874807 | SIADH | Phase 2 Phase 3 | Enrolling by invitation | April 2019 | Switzerland ... more >> University Hospital Basel Basel, Switzerland, 4031 Collapse << |
| NCT01634100 | Healthy | Phase 1 | Completed | - | Germany ... more >> 1245.83.1 Boehringer Ingelheim Investigational Site Biberach, Germany Collapse << |
| NCT02854748 | Diabetes Mellitus, Type II | Phase 1 | Unknown | September 2016 | Korea, Republic of ... more >> Dong A University Hospital Seo-gu, Busan, Korea, Republic of, 49201 Collapse << |
| NCT03448406 | Heart Failure | Phase 3 | Recruiting | June 7, 2019 | - |
| NCT01969747 | - | - | Completed | - | - |
| NCT01867307 | Diabetes Mellitus, Type 2 ... more >> Healthy Collapse << | Phase 2 | Completed | - | United States, Texas ... more >> Boehringer Ingelheim Investigational Site San Antonio, Texas, United States Collapse << |
| NCT03448419 | Heart Failure | Phase 3 | Recruiting | June 7, 2019 | - |
| NCT02102932 | - | - | Completed | - | - |
| NCT01969747 | Diabetes Mellitus, Type 1 | Phase 2 | Completed | - | Austria ... more >> 1245.78.43001 Boehringer Ingelheim Investigational Site Graz, Austria Germany 1245.78.49001 Boehringer Ingelheim Investigational Site Neuss, Germany Collapse << |
| NCT03332212 | Heart Failure | Phase 3 | Recruiting | October 31, 2019 | United Kingdom ... more >> John Radcliffe Hospital Recruiting Oxford, United Kingdom, OX3 9DU Contact: Masliza Mahmod +44 1865 220245 Masliza.mahmod@cardiov.ox.ac.uk Collapse << |
| NCT02848833 | - | - | Recruiting | December 31, 2019 | Korea, Republic of ... more >> Recruiting Multiple Locations, Korea, Republic of Collapse << |
| NCT03202667 | SIAD - Syndrome of Inappropria... more >>te Antidiuresis Hyponatremia Collapse << | Phase 2 Phase 3 | Recruiting | December 2018 | Switzerland ... more >> University Hospital Basel Recruiting Basel, Switzerland, 4031 Contact: Julie Refardt, Dr. +41(0)61 2652525 Zentrale julie.refardt@usb.ch Contact: Mirjam Christ-Crain, Prof mirjam.christ@usb.ch Collapse << |
| NCT02102932 | Healthy | Phase 1 | Completed | - | China ... more >> 1276.23.86002 Boehringer Ingelheim Investigational Site Beijing, China Collapse << |
| NCT01634100 | - | - | Completed | - | - |
| NCT03565458 | Type 2 Diabetes Mellitus | Phase 1 | Active, not recruiting | December 22, 2018 | Korea, Republic of ... more >> LG chem Seoul, Gangseo-Gu, Korea, Republic of, 07795 Collapse << |
| NCT03208465 | Diabetes Mellitus ... more >> Coronary Disease Collapse << | Phase 4 | Recruiting | April 30, 2021 | Korea, Republic of ... more >> Asan Medical Center Recruiting Seoul, Korea, Republic of Contact: Cheol-whan Lee, MD +82230103150 cheolwlee@amc.seoul.kr Principal Investigator: Cheol-Whan Lee, MD Collapse << |
| NCT03057977 | Heart Failure | Phase 3 | Recruiting | June 1, 2020 | - |
| NCT03215069 | Gestational Diabetes | Phase 3 | Not yet recruiting | September 1, 2021 | - |
| NCT02798744 | Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | June 2018 | United Kingdom ... more >> Leicester Diabetes Centre Recruiting Leicester, United Kingdom, LE5 4PW Contact: Natasha Wileman, MSc 0116 258 8929 ext 8929 natasha.wileman@uhl-tr.nhs.uk Contact: Lucy Ayres 0116 258 4499 ext 4499 lucy.ayres@uhl-tr.nhs.uk Principal Investigator: Melanie Davies, MBBS MD FRCP Collapse << |
| NCT02266472 | Healthy | Phase 1 | Completed | - | Germany ... more >> Boehringer Ingelheim Investigational Site Ingelheim, Germany Collapse << |
| NCT03057951 | Heart Failure | Phase 3 | Recruiting | June 1, 2020 | - |
| NCT03753087 | Heart Failure, Diastolic ... more >> Diabetes Mellitus, Type 2 Collapse << | Phase 4 | Not yet recruiting | May 2020 | Russian Federation ... more >> National Medical Research Center for Cardiology Not yet recruiting Moscow, Russian Federation, 121552 Contact: Anton Borisov, MD AntonBorisovMD@gmail.com Collapse << |
| NCT03639545 | Vascular Stiffness ... more >> Hypoglycemic Agents Diabetes Complications Diabetes Mellitus, Type 1 Collapse << | Phase 4 | Recruiting | January 30, 2019 | Slovenia ... more >> University Medical Centre Ljubljana Recruiting Ljubljana, Slovenia, SI-1000 Contact: Mojca Lunder, MD, PhD +386 1 5223140 mojca.lunder@kclj.si Contact: Andrej Janez, Prof +386 1 5223564 andrej.janez@kclj.si Principal Investigator: Miodrag Janic, MD, PhD Principal Investigator: Miso Sabovic, Prof Collapse << |
| NCT03227484 | PreDiabetes B... more >>ody Weight Collapse << | Phase 2 | Recruiting | October 2019 | Germany ... more >> University of Tuebingen, Department of Internal Medicine IV Recruiting Tübingen, Germany, 72076 Contact: Martin Heni, MD +49 7071 29 82714 martin.heni@med.uni-tuebingen.de Contact: Andreas Fritsche, MD +49 7071 29 82714 andreas.fritsche@med.uni-tuebingen.de Collapse << |
| NCT02637973 | Type 2 Diabetes ... more >> Non-alcoholic Fatty Liver Disease Collapse << | Phase 4 | Unknown | July 2018 | Germany ... more >> Charite Universitaetsmedizin Berlin Recruiting Berlin, Germany Contact: Gabriele Klampke +49 30 450514422 gabriele.klampke@charite.de Principal Investigator: Andreas Pfeiffer, Professor Sub-Investigator: Stefan Kabisch, MD Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Recruiting Dresden, Germany, 01307 Contact: Andreas Birkenfeld, Prof., M.D. andreas.birkenfeld@uniklinikum-dresden.de German Diabetes Center Recruiting Dusseldorf, Germany Contact: Sofiya Gancheva, MD +49 221 3382 698 sofiya.gancheva@ddz.uni-duesseldorf.de Contact: Michael Roden, Professor +49 211 3382 201 michael.roden@ddz.uni-duesseldorf.de Principal Investigator: Michael Roden, Professor Sub-Investigator: Sofiya Gancheva, MD University Clinic Heidelberg Recruiting Heidelberg, Germany Contact: Bischoff Sandra +49 6221 56 8606 sandra.bischoff@med.uni-heidelberg.de Principal Investigator: Christian Kasperk, Professor Sub-Investigator: Stefan Kopf, MD University Clinic Tübingen Recruiting Tübingen, Germany Contact: Louise Fritsche, PhD +49 7071 29 80687 Louise.Fritsche@med.uni-tuebingen.de Principal Investigator: Norbert Stefan, Professor Sub-Investigator: Andreas Fritsche, Professor Collapse << |
| NCT03200860 | Heart Failure Acute ... more >> Heart Failure，Congestive Heart Failure; With Decompensation Collapse << | Phase 2 | Recruiting | December 2019 | Netherlands ... more >> University Medical Center Groningen Recruiting Groningen, Netherlands, 9700RB Contact: Kevin Damman, MD,PhD 0031503616161 Principal Investigator: Kevin Damman, MD,PhD Collapse << |
| NCT02266472 | - | - | Completed | - | - |
| NCT02632747 | Diabetes Mellitus, Type 1 ... more >> Diabetes Mellitus, Type 2 Obesity Collapse << | Phase 2 | Recruiting | September 9, 2019 | Canada, Ontario ... more >> Toronto General Hospital Recruiting Toronto, Ontario, Canada, M5G 2N2 Collapse << |
| NCT02230995 | Healthy | Phase 1 | Completed | - | Germany ... more >> Boehringer Ingelheim Investigational Site Biberach an der Riss, Germany Collapse << |
| NCT02230995 | - | - | Completed | - | - |
| NCT03027960 | Heart Failure ... more >> Type II; Diabetes Collapse << | Phase 2 | Enrolling by invitation | June 2022 | United States, Connecticut ... more >> Yale New Haven Hospital New Haven, Connecticut, United States, 06511 Collapse << |
| NCT03363464 | - | - | Active, not recruiting | November 15, 2021 | United States, Massachusetts ... more >> Bringham Women Hospital Boston, Massachusetts, United States, 02120 Collapse << |
| NCT02758171 | Healthy | Phase 1 | Completed | - | Germany ... more >> Humanpharmakologisches Zentrum Biberach Biberach, Germany, 88397 Collapse << |
| NCT02815644 | - | - | Completed | - | - |
| NCT02758171 | - | - | Completed | - | - |
| NCT02964715 | Type2 Diabetes ... more >> NAFLD Collapse << | Phase 4 | Recruiting | November 2018 | Malaysia ... more >> University of Malaya Recruiting Kuala Lumpur, Wilayah Persekutuan, Malaysia Contact: Shireene R Vethakkan, MD 0162093355 shireene.vethakkan@gmail.com Sub-Investigator: Wah K Chan, MRCP Collapse << |
| NCT02815644 | Healthy | Phase 1 | Completed | - | Japan ... more >> SOUSEIKAI Sumida Hospital Tokyo, Sumida-ku, Japan, 133-0004 Collapse << |
| NCT03485092 | Heart Failure ... more >> Diabetes Mellitus Collapse << | Phase 4 | Recruiting | February 28, 2020 | United Kingdom ... more >> Queen Elizabeth University Hospital Recruiting Glasgow, Scotland, United Kingdom, G51 4TF Contact: Mathew Lee, MBChB 0141 232 7600 matthewlee1@nhs.net Contact: Ann Wright, RCN 0141 232 7600 ann.wright@nhs.net Principal Investigator: Mark Petrie, MBChB Collapse << |
| NCT03437330 | Type2 Diabetes Mellitus | Phase 4 | Not yet recruiting | March 31, 2019 | - |
| NCT03642184 | New Onset Diabetes After Trans... more >>plant Kidney Transplant; Complications Collapse << | Phase 4 | Recruiting | December 31, 2020 | China, Shanghai ... more >> Department of nephrology, endocrinology and kidney transplantation , Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine Recruiting Shanghai, Shanghai, China, 200127 Contact: Shan Mou, Dr. +8613918221242 shan_mou@126.com Collapse << |
| NCT02401880 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | Germany ... more >> Profil Mainz GmbH & Co. KG Mainz, Germany, 55116 Profil Institut für Stoffwechselforschung GmbH Neuss, Germany, 41460 Collapse << |
| NCT03087773 | Acute Myocardial Infarction | Phase 3 | Recruiting | April 2, 2020 | Austria ... more >> Klinikum Klagenfurt am Wörthersee Recruiting Klagenfurt, Kärnten, Austria, 9020 Contact: Carl Kaulfersch, MD Barmherzige Brüder Konventhospital Linz Not yet recruiting Linz, Oberösterreich, Austria, 4021 Contact: Martin Clodi, Univ.-Prof. VIVIT Institut am akademischen Lehrkrankenhaus Feldkirch Recruiting Feldkirch, Vorarlberg, Austria, 6800 Contact: Christoph Säly, Univ.-Prof. Medical University of Graz Recruiting Graz, Austria, 8036 Contact: Dirk von Lewinski, Assoc.-Prof. dirk.von-lewinski@medunigraz.at Uniklinikum Salzburg Recruiting Salzburg, Austria, 5020 Contact: Uta Hoppe, Univ.-Prof. Krankenanstalt Rudolfstiftung Not yet recruiting Vienna, Austria, 1030 Contact: Franz Weidinger, Univ.-Prof. AKH Vienna Recruiting Vienna, Austria, 1090 Contact: Jolanta Siller-Matula, Assoc.-Prof. Collapse << |
| NCT03157414 | Diabetes Mellitus ... more >> Renal Insufficiency Safety Issues Collapse << | Phase 4 | Active, not recruiting | July 2018 | Norway ... more >> Oslo University Hospital Rikshospitalet Oslo, Norway, 0424 Collapse << |
| NCT02577315 | Healthy | Phase 1 | Completed | - | Russian Federation ... more >> 1276.27.001 Boehringer Ingelheim Investigational Site St. Petersburg, Russian Federation Collapse << |
| NCT02577315 | - | - | Completed | - | - |
| NCT02752113 | Diabetes Mellitus Type 2 | Phase 3 | Recruiting | January 2019 | Germany ... more >> Clinical Research Center, Dept of Nephrology and Hypertenison, University of Erlangen/Nürnberg Recruiting Erlangen, Bavaria, Germany, 91054 Contact: Christian Ott, MD +49-9131-85 ext 36245 christian.ott@uk-erlangen.de Contact: Roland Schmieder, Prof. MD +49 9131 85 ext 36245 roland.schmieder@uk-erlangen.de Principal Investigator: Roland Schmieder, Prof. MD Sub-Investigator: Christian Ott, MD Collapse << |
| NCT03132181 | Diabetes Mellitus Type 2 (T2DM... more >>) Collapse << | Phase 2 | Recruiting | June 30, 2019 | Germany ... more >> Department of Internal Medicine I RWTH Aachen University Hospital Recruiting Aachen, NRW, Germany, 52074 Contact: Michael Lehrke, PD Dr. med. +49 241 80 85152 mlehrke@ukaachen.de Principal Investigator: Michael Lehrke, PD Dr. med. Sub-Investigator: Nikolaus Marx, Univ.-Prof. Dr. med. Collapse << |
| NCT03254849 | Type 2 Diabetes Mellitus | Phase 4 | Recruiting | September 15, 2019 | Germany ... more >> Profil Institut für Stoffwechselforschung GmbH Recruiting Neuss, North Rhine-Westphalia, Germany, 41460 Contact: Maren Lübkert +49 2131 4018 146 maren.luebkert@profil.com Principal Investigator: Tim Heise, MD Collapse << |
| NCT03078101 | Diabetic Kidney Disease ... more >> Diabetes Mellitus, Type 2 Chronic Kidney Disease stage3 Chronic Kidney Disease stage4 Collapse << | Phase 2 | Recruiting | August 2019 | Austria ... more >> Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria Recruiting Vienna, Austria, 1090 Contact: Manfred Hecking, MD manfred.hecking@meduniwien.ac.at Contact: Marlies Antlanger, MD marlies.antlanger@meduniwien.ac.at Collapse << |
| NCT03059056 | Diabetes Mellitus | Phase 1 | Completed | - | - |
| NCT03771781 | Type 2 Diabetes | Not Applicable | Completed | - | China, Hunan ... more >> The Third Hospital of Changsha Changsha, Hunan, China, 410000 Collapse << |
| NCT02998970 | Diabetes Card... more >>iovascular Disease Collapse << | Phase 4 | Active, not recruiting | September 2018 | Canada, Ontario ... more >> St. Michael's Hospital Toronto, Ontario, Canada, M5B 1W8 Collapse << |
| NCT03554200 | Diabetes Mellitus, Type 2 ... more >> Acute Heart Failure Collapse << | Phase 2 | Recruiting | May 2020 | Germany ... more >> Department of Internal Medicine I RWTH Aachen University Hospital Recruiting Aachen, NRW, Germany, 52074 Contact: Michael Lehrke, PD Dr. med. +49 241 80 85152 mlehrke@ukaachen.de Principal Investigator: Michael Lehrke, PD Dr. med. Sub-Investigator: Nikolaus Marx, Univ.-Prof. Dr. med. Collapse << |
| NCT02686476 | Non Alcoholic Fatty Liver Dise... more >>ase Collapse << | Not Applicable | Completed | - | India ... more >> Division Of Endocrinology , Medanta The Medicity Sec 38 Gurgaon, Haryana, India, 122001 Collapse << |
| NCT03008551 | Polycystic Ovary Syndrome | Phase 2 Phase 3 | Completed | - | United Kingdom ... more >> Michael White Centre for Diabetes and Endocrinology Hull, East Yorkshire, United Kingdom, HU3 2RW Collapse << |
| NCT03271879 | Heart Failure ... more >> Diabetes Mellitus Arrythmia Collapse << | Phase 4 | Not yet recruiting | June 1, 2020 | - |
| NCT02932436 | Diabetes Mellitus, Type 2 ... more >> Diastolic Dysfunction Collapse << | Phase 4 | Recruiting | June 2019 | Germany ... more >> Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kardiologie, Präventive Kardiologie und Medizinische Prävention Recruiting Mainz, Germany, 55131 Contact: Philipp Wild, MD 00496131 ext 17 170 philipp.wild@unimedizin-mainz.de Contact: Tommaso Gori, MD 00496131 ext 17 170 tommaso.gori@unimedizin-mainz.de Collapse << |
| NCT03113110 | Posttransplant Diabetes Mellit... more >>us Collapse << | Phase 2 | Recruiting | December 31, 2019 | Austria ... more >> Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria Recruiting Vienna, Austria, 1090 Contact: Manfred Hecking, MD manfred.hecking@meduniwien.ac.at Contact: Elisabeth Schwaiger, MD elisabeth.schwaiger@meduniwien.ac.at Collapse << |
| NCT03093103 | Nephropathy | Phase 2 | Recruiting | December 31, 2018 | Switzerland ... more >> Service de Néphrologie Recruiting Lausanne, Vaud, Switzerland, 1011 Contact: Guler Gok-sogut, Ass-med 41 79 556 20 05 guler-gok-sogut@chuv.ch Contact: Marie-Eve Muller, MD 41 79 556 59 46 Marie-Eve.Muller@chuv.ch Sub-Investigator: Anne Zanchi, MD Principal Investigator: Michel Burnier, Prof Collapse << |
| NCT03030222 | Heart Failure | Phase 4 | Recruiting | June 2019 | United States, California ... more >> University of Southern California Recruiting Los Angeles, California, United States, 90033 Contact: Study Coordinator 323-442-7983 United States, Florida First Coast Cardiovascular Institute Recruiting Jacksonville, Florida, United States, 32256 Contact: Study Coordinator 904-493-3333 United States, Illinois NorthShore University Health System Research Institute Recruiting Evanston, Illinois, United States, 60201 Contact: Study Coordinator 847-570-2912 United States, Minnesota CentraCare Heart and Vascular Center Recruiting Saint Cloud, Minnesota, United States, 56303 Contact: Study Coordinator 320-251-2700 ext 58482 United States, New York St. Francis Hospital Recruiting Roslyn, New York, United States, 11576 Contact: Study Coordinator 516-562-6790 United States, Ohio Ohio State University Recruiting Columbus, Ohio, United States, 43210 Contact: Study Coordinator 614-247-7133 United States, Texas Austin Heart Clinical Research Recruiting Austin, Texas, United States, 78756 Contact: Study Coordinator 512-206-3602 Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Study Coordinator 713-798-1037 United States, Virginia Sentara Cardiovascular Research Institute Recruiting Norfolk, Virginia, United States, 23507 Contact: Study Coordinator 757-388-2732 Collapse << |
| NCT02471963 | Diabetes Mellitus Type 2 | Phase 3 | Completed | - | Germany ... more >> University of Erlangen-Nuremberg Erlangen, Bavaria, Germany, 91054 Collapse << |
| 靶点 | Description | IC50 |
|---|---|---|
| SGLT2 | IC50:3.1nM |
